Skip to content

Helena Carmo

REQUIMTE, Toxicology Department, Faculty of Pharmacy, University of Porto, Rua Aníbal Cunha 164, 4050-047 Porto, Portugal. helenacarmo@ff.up.pt

4 papers in the library · 117 citations · publishing 2004-2026

Papers

Metabolic pathways of 4-bromo-2,5-dimethoxyphenethylamine (2C-B): analysis of phase I metabolism with hepatocytes of six species including human.

Toxicology January 5, 2005 Helena Carmo, Jan G Hengstler, Douwe De Boer et al. 85 citations

The psychoactive designer drug 2C-B is broken down by liver cells from humans, monkeys, dogs, rabbits, rats, and mice through oxidative deamination and demethylation, producing several metabolites. A previously unknown metabolite, 4-bromo-2,5-dimethoxy-phenol (BDMP), appeared only in mouse cells, while another metabolite, 2-(4-bromo-2-hydroxy-5-methoxyphenyl)-ethanol (B-2-HMPE), formed in human, monkey, and rabbit cells but not in dog, rat, or mouse cells. Toxic effects on liver cells varied little across species but showed large differences among cells from three human donors, indicating that individual human variation may be more important than species differences in determining 2C-B toxicity.

Metabolism of the designer drug 4-bromo-2,5-dimethoxyphenethylamine (2C-B) in mice, after acute administration.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences November 25, 2004 Helena Carmo, Douwe De Boer, Fernando Remião et al. 32 citations

The psychoactive drug 2C-B, sold as 'Ecstasy', is metabolized in mice, producing several metabolites detectable in urine by GC/MS. Unchanged 2C-B and these metabolites were identified, providing data that may help understand the drug's biological and toxicological effects and aid forensic analysis of samples from human abusers.

Impact of psilocybin and Psilocybe cubensis extract on gut microbiota in Wistar Han rats

Science Letters April 17, 2026 Francisco Sacadura, Cláudia Marques, Andreia Machado Brito-Da-Costa et al.

Both pure psilocybin and a Psilocybe cubensis extract altered the gut microbiota of male Wistar Han rats over two weeks. Fecal samples analyzed by 16S rRNA amplicon sequencing showed that microbial community structure shifted away from baseline and control profiles at day 7 and diverged further by day 14. The effect was more pronounced in rats given pure psilocybin than in those given the whole mushroom extract, suggesting the extract's additional compounds may modulate the impact. The results indicate a time-dependent modulation of gut microbiota by both treatments, with differential magnitude between the pure compound and the whole extract.

Psilocybin and Psilocybe cubensis extract exhibit divergent behavioural and toxicological effects in rats

Science Letters April 17, 2026 Diana Dias Da Silva, Andreia Machado Brito-Da-Costa, Francisco Sacadura et al.

Pure psilocybin and whole Psilocybe cubensis extract produce distinct behavioral and toxicological effects in male Wistar Han rats. Pure psilocybin decreased conditioned place preference scores at days 1 and 7, indicating aversive or non-reinforcing effects, and reduced exploratory activity. The extract did not significantly alter preference but transiently increased exploratory behavior at day 7. Peripherally, pure psilocybin increased relative liver weight, suggesting hepatic stress, while the extract reduced renal lipid peroxidation, indicating a protective or antioxidant effect likely from other compounds. These differences highlight the importance of matrix effects in psychedelic research.